Caris Life Sciences, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Caris Life Sciences, Inc. (NASDAQ:CAI) is a molecular diagnostics company that specializes in precision oncology through advanced AI-driven molecular profiling and sequencing technologies. The company offers comprehensive molecular profiling services, including whole exome sequencing (WES) and whole transcriptome sequencing (WTS) for solid and hematologic tumors; Caris Assure, a pan-cancer blood-based assay utilizing circulating nucleic acid sequencing (cNAS) for therapy selection; MI Cancer Seek, an FDA-approved companion diagnostic for solid tumor profiling in adult and pediatric patients; and liquid biopsy platforms for multi-cancer early detection (MCED), minimal residual disease (MRD) monitoring, and therapy guidance, supported by one of the world's largest clinico-genomic databases exceeding 660,000 patient records. Caris serves oncologists, patients, and biopharma partners across the continuum of cancer care, from early detection and diagnosis to therapy selection and drug development, with applications extending to non-oncology areas such as cardiology and neurology. Founded in 2008 and headquartered in Irving, Texas, the company operates labs and offices in Phoenix, New York, Cambridge, Tokyo, and Basel, providing services in the United States, Europe, Australia, and other international markets. Recent developments include a $168 million growth capital raise in April 2025 led by Braidwell LP with participation from Perceptive Advisors, Woodline, and others, bringing total funding since 2018 to $1.86 billion; the commercial launch of Caris Assure in 2024 following FDA approval of MI Cancer Seek; strategic partnerships such as a January 2024 multimodal data collaboration with Flatiron Health and an April 2024 antibody-drug conjugate alliance with Merck potentially worth up to $1.4 billion in milestones; and the launch of its initial public offering roadshow in June 2025, with shares listed on Nasdaq under CAI.
Company News
Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer
Caris Life Sciences study finds AI tool could guide pancreatic cancer treatment choice
Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer
Caris Life Sciences: Guidance Raised, Valuation Still Attractive
Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript
Caris Life Sciences,?Inc. (CAI) Reports Break-Even Earnings for Q2
Caris Life Sciences Q2 Earnings Call Highlights
Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Caris Life Sciences: Disrupting Cancer Screening And Therapy Selection
Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026
Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing
Caris Life Sciences Launches Caris Detect, the World's Most Sensitive and Comprehensive Multi-Cancer Early Detection Blood Test
Virginia Information Technologies Agency Selects CAI to Deliver Statewide Cybersecurity Services to Local Governments
CAI Named to Newsweek's America's Greatest Workplaces in Tech 2026
Caris Life Sciences Announces Dual Listing on NYSE Texas
Caris Life Sciences: The Discount To Peers Looks Hard To Ignore
Caris Life Sciences, Inc. (CAI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Caris Life Sciences Announces Share Repurchase Program
Capitan Investment Ltd. Announces Adoption of Semi-Annual Reporting
Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing